OXFORD, UK, April 24 /PRNewswire-FirstCall/ -- Oxford GlycoSciences Plc (LSE: OGS, Nasdaq: OGSI) has been informed that a 66 year-old patient, formerly in the OGT 918-001 trial, who continued in the extended use capture protocol but stopped treatment with OGT 918 in October 2001, developed cognitive dysfunction of unknown cause. The patient is still under investigation and a diagnosis has not yet been established. There are other potential causative factors relevant to this event, and according to WHO criteria, a relationship to drug treatment appears unlikely at this time.
The Ethics Committee in Israel has abstained from expressing any opinion about a possible relationship until the results of the ongoing tests are obtained, and recommended that OGT 918 administration be temporarily stopped as a precaution, pending the outcome of the clinical investigations. All Investigators and relevant Regulatory Authorities are being informed.
Dr. Chris Moyses, Chief Medical Officer of OGS, said, ``We are working with the investigator to clarify this issue and, whilst a relationship to drug treatment appears unlikely, treatment has been withdrawn purely as a precautionary measure.''... |
